why choose us

First received: March 20, 2023

Clinical Trial: A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus

Study Status: Completed

Recruit Status: RECRUITING

Condition: Systemic Lupus Erythematosus

Study Type: INTERVENTIONAL


Official Title: A Phase Ib, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 Followi

Brief Summary: The main purpose of this study is to evaluate the safety and tolerability of CUG252 following multiple ascending doses in participants with Systemic Lupus Erythematosus (SLE).

Read more